Category Archives: Strategy

Pfizer Adds FoldRx to its Specialty Care Unit

By George Koroneos | Published: September 1, 2010
Pfizer on Wednesday announced that it acquired a small rare-disease drug firm, FoldRx, for an undisclosed sum of money. Pfizer spokeswoman Gwen Fischer told Pharm Exec that the deal came together in a matter of weeks, and that FoldRx will be fully incorporated into Pfizer’s research division. All of FoldRx’s employees are expected to become Pfizer [...]
Also posted in Deals | Tagged , , | Leave a comment

New Study Shows Spike in Branded Drug Prices (Updated 8/26)

By George Koroneos | Published: August 25, 2010
The retail price of branded pharmaceuticals spiked 8.3 percent in 2009, according to a new report released by AARP on Wednesday. This is the first time AARP has measured the retail price of Rx drugs. In the past, the lobby group only tracked the wholesale manufacturers’ price of generic, branded, and specialty drugs, which is traditionally [...]
Also posted in Sales | Leave a comment

Options for Oncologists Get Tougher

By William Looney | Published: August 4, 2010
How does the business of oncology practice fare today? The National Comprehensive Cancer Care Network (NCCN), which allies 21 of the world’s leading cancer care and research centers in developing state-of-the-art practice guidelines, decided to ask that question in a survey it conducted among several hundred oncology specialists earlier this year. The results, a sobering [...]
Posted in Strategy | Tagged , , | 2 Comments

Why Won’t Andrew Witty Take the Dive? (Updated 7/30/10)

By Walter Armstrong | Published: July 29, 2010
AIDS: An epidemic without end. It’s mostly fallen off the front pages—who has time or money or compassion for a decades-old global health crisis when we’ve got our own global economic crisis?—except for every two years when the International AIDS Conference comes around. The one held in Vienna last week earned some ink, but the [...]
Posted in Strategy | 2 Comments

Merck KGaA MS Drug on the Fast Track

By George Koroneos | Published: July 28, 2010
Merck KGaA received word July 25 that its application for the multiple sclerosis treatment Cladribine had received priority review status by FDA, decreasing the evaluation period from 10 months to six months, and closing the gap between Merck and the competition. “This is a critical milestone on the path to potential approval for short-course therapy with [...]
Posted in Strategy | Tagged , , , , , , , , | Leave a comment